Kailera Therapeutics
Kailera Therapeutics Raises $400 Million in Series A - October 2024
Quick Facts
Kailera Therapeutics Raises $400 Million in Series A - October 2024
Executive Summary
Kailera Therapeutics raised a massive $400 million Series A to develop clinical-stage injectable and oral therapies for chronic weight management and metabolic diseases.
Funding Amount: $400 Million
Valuation: Undisclosed
Round Type: Series A
Announced: October 2024
Headquarters: Boston, MA
Category: Biotechnology
About Kailera Therapeutics
Kailera Therapeutics was founded in 2023 and is headquartered in Boston, MA. The company currently employs 50+ people and operates in the Biotechnology sector.
Kailera Therapeutics raised a massive $400 million Series A to develop clinical-stage injectable and oral therapies for chronic weight management and metabolic diseases.
Funding Round Details
Investment Amount
Kailera Therapeutics successfully raised $400 Million in this Series A funding round, announced in October 2024.
The company has not disclosed its valuation.
Lead Investors & Participants
Atlas Venture (Co-Lead): Life sciences venture capital firm
Bain Capital Life Sciences (Co-Lead): Healthcare-focused growth equity
RTW Investments (Co-Lead): Healthcare hedge fund
GV (Google Ventures) (Venture Capital): Google's venture arm
T. Rowe Price (Institutional Investor): Global asset manager
Use of Funds
Advancing clinical trials for weight management therapies, developing oral GLP-1 medications, and expanding R&D capabilities in metabolic disease treatment.
The capital will enable Kailera Therapeutics to:
- Accelerate product development and innovation
- Expand market reach and customer acquisition
- Scale operations and infrastructure
- Strengthen the team with key hires
- Invest in research and development
Key Metrics & Achievements
- One of largest biotech Series A rounds ever
- Clinical-stage therapies in development
- Targeting $100+ billion weight management market
- Multiple drug candidates in pipeline
- Competing in GLP-1 obesity drug market
Business Model
Kailera develops and commercializes weight management therapies, initially targeting obesity and related metabolic disorders through both injectable and oral medications.
Market Opportunity & Competition
Competes with Novo Nordisk (Ozempic/Wegovy), Eli Lilly (Mounjaro/Zepbound), and other biotech companies developing GLP-1 receptor agonists.
The Biotechnology market continues to experience rapid growth, with increasing demand from enterprises and consumers. Kailera Therapeutics is well-positioned to capitalize on this opportunity with its differentiated technology and strong investor backing.
What This Means for the Industry
This significant funding round demonstrates strong investor confidence in Kailera Therapeutics's vision and execution. The $400 Million investment positions the company to:
- Accelerate Innovation: Develop next-generation products and features
- Expand Market Leadership: Capture greater market share in Biotechnology
- Scale Operations: Build infrastructure to support rapid growth
- Attract Top Talent: Recruit world-class engineers, researchers, and business leaders
- Drive Industry Transformation: Shape the future of Biotechnology
Company Background
Founded: 2023
Headquarters: Boston, MA
Employees: 50+
Industry: Biotechnology
Total Funding: $400 Million+ (this round)
Looking Ahead
With this substantial funding, Kailera Therapeutics is positioned for continued growth and innovation in the Biotechnology space. The company plans to leverage the capital to expand its market presence, enhance its product offerings, and solidify its position as a leader in the industry.
Investors and industry analysts will be closely watching Kailera Therapeutics as it executes on its ambitious growth plans and works to deliver value to customers and shareholders.
About the Investors
Atlas Venture: Life sciences venture capital firm
Bain Capital Life Sciences: Healthcare-focused growth equity
RTW Investments: Healthcare hedge fund
This funding announcement was verified through official press releases, SEC filings, and credible news sources including Crunchbase, TechCrunch, and Bloomberg.
Last Updated: October 26, 2025
Key Investors
About the Author
Related Company Reports
Electra Therapeutics Raises $183 Million in Series C - October 22, 2024
Electra Therapeutics announced $183 Million in Series C funding at a Undisclosed valuation. Electra Therapeutics raised an oversubscribed $183 million Series C to advance clinical trials for novel immunology therapies targeting autoimmune and...
Citius Pharmaceuticals Headquarters - Office Location & Address
Discover Citius Pharmaceuticals's headquarters at 11 Commerce Dr, Cranford, NJ 07016. Critical care therapeutics developer. Learn about the office facilities and work environment.
Chronos Therapeutics Headquarters - Office Location & Address
Discover Chronos Therapeutics's headquarters at Botley Rd, Oxford, OX2 0JD. Chronopharmacology therapeutics developer. Learn about the office facilities and work environment.